12:00 AM
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sativex regulatory update

GW Pharma said the U.K. rescheduled Sativex to treat spasticity due to multiple sclerosis to Schedule 4, Part 1, of the U.K. Drug Act, now allowing the cannabinoid drug to be prescribed in the U.K. with no restriction on supply, recording, storage or...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >